ArticleWorld journal of surgical oncology2025
The diagnostic value of a breast cancer diagnosis model based on serum MiRNAs and serum tumor markers.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating microRNAs as Early Biomarkers of Breast Cancer: A Nested Case-Control Study Within a Prospective Cohort in Italy.International journal of molecular sciences · 2026Article
- miR-1911-3p Regulates Malignant Biological Behaviors and Glycolytic Activity of Triple-Negative Breast Cancer via FBLN5.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBreast cancer (BCa) is the leading cause of cancer-related death among women worldwide. MicroRNAs (miRNAs) are promising tools for diagnosis and prognosis. This study investigated the role of serum miRNAs and tumor markers (TMs) in the diagnosis of BCa.
methodsDifferentially expressed miRNAs were screened from serum samples of BCa patients and healthy individuals via high-throughput sequencing. The expression of hsa-miR-1911-3p, hsa-miR-4694-5p, hsa-miR-548ao-5p, and hsa-miR-4804-3p in 169 BCa patients and 116 healthy controls was detected via qRT-PCR. Serum tumor-associated antigens were detected by chemiluminescence. Logistic regression was subsequently used to develop the miRNA panel I, TM panel II, and (miRNA + TM) panel III models. Receiver operating characteristic (ROC) curve, precision-recall (PR) curve and decision curve analyses (DCA) were performed to assess the accuracy of the three models for BCa diagnosis. Additionally, the relationships between miRNA expression and the clinical characteristics of patients with BCa were assessed.
resultsFour serum miRNAs (hsa-miR-1911-3p, hsa-miR-548ao-5p, hsa-miR-4694-5p, and hsa-miR-4804-3p) were newly associated with BCa. The miRNA panel I based on hsa-miR-548ao-5p and hsa-miR-4804-3p showed greater diagnostic effectiveness for BCa than TM panel II based on cancer antigen 125 (CA125) and cancer antigen 153 (CA153), with AUC values of 0.816 and 0.777, respectively. (miRNA + TM) panel III had higher diagnostic effectiveness than miRNA panel I, with an AUC value of 0.870. The expression of miR-548ao-5p and miR-4804-3p is closely related to clinical features, such as human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), HER2-enriched subtype, stage III/IV, and lymph node-transplanted breast cancer.
conclusionMiR-548ao-5p and miR-4804-3 could serve as potential biomarkers for the diagnosis of BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.